Dong Xiaomin, Deng Yi-Mo, Aziz Ammar, Whitney Paul, Clark Julia, Harris Patrick, Bautista Catherine, Costa Anna-Maria, Waller Gregory, Daley Andrew J, Wieringa Megan, Korman Tony, Barr Ian G
WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, 3000, Australia; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, 3000, Australia.
Queensland Children's Hospital, Brisbane, QLD, 4101, Australia; Children's Health Queensland Hospital & Health Service, Brisbane, QLD, 4101, Australia.
J Clin Virol. 2023 Apr;161:105423. doi: 10.1016/j.jcv.2023.105423. Epub 2023 Mar 12.
Human Respiratory Syncytial Virus (RSV) infections pose a significant risk to human health worldwide, especially for young children. Whole genome sequencing (WGS) provides a useful tool for global surveillance to better understand the evolution and epidemiology of RSV and provide essential information that may impact on antibody treatments, antiviral drug sensitivity and vaccine effectiveness.
Here we report the development of a rapid and simplified amplicon-based one-step multiplex reverse-transcription polymerase chain reaction (mRT-PCR) for WGS of both human RSV-A and RSV-B viruses.
Two mRT-PCR reactions for each sample were designed to generate amplicons for RSV WGS. This new method was tested and evaluated by sequencing 206 RSV positive clinical samples collected in Australia in 2020 and 2021 with RSV Ct values between 10 and 32.
In silico analysis and laboratory testing revealed that the primers used in the new method covered most of the currently circulating RSV-A and RSV-B. Amplicons generated were suitable for both Illumina and Oxford Nanopore Technologies (ONT) NGS platforms. A success rate of 83.5% with a full coverage for the genome of 98 RSV-A and 74 RSV-B was achieved from all clinical samples tested.
This assay is simple to set up, robust, easily scalable in sample preparation and relatively inexpensive, and as such, provides a valuable addition to existing NGS RSV WGS methods.
人类呼吸道合胞病毒(RSV)感染对全球人类健康构成重大风险,尤其是对幼儿。全基因组测序(WGS)为全球监测提供了一个有用的工具,以更好地了解RSV的进化和流行病学,并提供可能影响抗体治疗、抗病毒药物敏感性和疫苗有效性的重要信息。
在此,我们报告了一种快速、简化的基于扩增子的一步多重逆转录聚合酶链反应(mRT-PCR)方法的开发,用于人类RSV-A和RSV-B病毒的全基因组测序。
为每个样本设计了两个mRT-PCR反应,以生成用于RSV全基因组测序的扩增子。通过对2020年和2021年在澳大利亚收集的206份RSV阳性临床样本进行测序,对这种新方法进行了测试和评估,这些样本的RSV Ct值在10到32之间。
计算机分析和实验室测试表明,新方法中使用的引物覆盖了目前大多数流行的RSV-A和RSV-B。生成的扩增子适用于Illumina和牛津纳米孔技术(ONT)的二代测序平台。在所有测试的临床样本中,98株RSV-A和74株RSV-B的基因组覆盖率达到了83.5%。
该检测方法易于设置、稳健、在样本制备中易于扩展且相对便宜,因此为现有的二代测序RSV全基因组测序方法提供了有价值的补充。